As of November 10, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Akari Therapeutics Plc. The largest reported stake is Hoyoung Huh, M.D., Ph.D.'s, at 18.4%. 6 filings are on record since March 4, 2026 (Schedule 13G/A, March 4, 2026).
Sell to companies like Akari Therapeutics Plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Bank of Montreal · Sole voting: 0 · Shared voting: 8,000,000,000 · Sole dispositive: 0 · Shared dispositive: 8,000,000,000 · SCHEDULE 13G, 2026-08-12
- · Holder: White Lion Capital LLC · Percent: 5% · Shares: 7,001,638,477 · SCHEDULE 13G
- · Reporting person: MMCAP International Inc. SPC · Sole voting: 0 · Shared voting: 8,000,000,000 · Sole dispositive: 0 · Shared dispositive: 8,000,000,000 · SCHEDULE 13G, 2026-06-08
- · Holder: Hoyoung Huh, M.D., Ph.D. · Percent: 18.4% · SCHEDULE 13G/A
- · Holder: Samir R. Patel · Percent: 10.4% · SCHEDULE 13D/A
Akari Therapeutics Plc has 6 Schedule 13D or 13G filings on record since 2026-03-04. 6 holders' latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Hoyoung Huh, M.D., Ph.D. | 18.4% | 18,199,697,667 | SCHEDULE 13G/A, 2026-03-04 | 2026-03-02 |
| 10.4% | 9,725,215,000 | SCHEDULE 13D/A, 2026-03-04 | 2026-03-02 | |
| Ray Prudo, M.D. | 8.9% | 8,391,326,467 | SCHEDULE 13D/A, 2026-03-04 | 2026-03-02 |
| MMCAP International Inc. SPC | 8% | 8,000,000,000 | SCHEDULE 13G, 2026-06-08 | 2026-06-02 |
| Bank of Montreal | 5.71% | 8,000,000,000 | SCHEDULE 13G, 2026-08-12 | 2026-06-30 |
| White Lion Capital LLC | 5% | 7,001,638,477 | SCHEDULE 13G, 2026-08-07 | 2026-08-07 |
Holding shares or following this stake? See who's behind Akari Therapeutics Plc and the warning signs.
Free to see. No signup.
Keep reading
More on Akari Therapeutics Plc and the records around it.
Akari Therapeutics Plc elsewhere on the record
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- White Lion Capital LLC also filed stake reports on 4 other companies: Actelis Networks, Inc. (Jul 2026), CID Holdco, Inc. (Jun 2026), RELIANCE GLOBAL GROUP, INC. (Sep 2025)
- Bank of Montreal also filed stake reports on 49 other companies: Alarm.com Holdings, Inc. (Aug 2026), North American Construction Group Ltd. (Aug 2026), OPENLANE, Inc. (Aug 2026)
- MMCAP International Inc. SPC also filed stake reports on 52 other companies: BHAV Acquisition Corp II (Nov 2026), Haymaker Acquisition Corp V (Sep 2026), Thunder Bridge Capital Partners V, Ltd. (Aug 2026)
Watch Akari Therapeutics Plc
Get an email when Akari Therapeutics Plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Akari Therapeutics Plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Akari Therapeutics Plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Akari Therapeutics Plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| MMCAP International Inc. SPC | 0 | 8,000,000,000 | 0 | 8,000,000,000 | SCHEDULE 13G, 2026-06-08 |
| MM Asset Management Inc. | 0 | 8,000,000,000 | 0 | 8,000,000,000 | SCHEDULE 13G, 2026-06-08 |
| Bank of Montreal | 0 | 8,000,000,000 | 0 | 8,000,000,000 | SCHEDULE 13G, 2026-08-12 |
| Bank Of Montreal Holding Inc. | 0 | 8,000,000,000 | 0 | 8,000,000,000 | SCHEDULE 13G, 2026-08-12 |
| Bmo Nesbitt Burns Inc. | 0 | 8,000,000,000 | 0 | 8,000,000,000 | SCHEDULE 13G, 2026-08-12 |
| White Lion Capital LLC | 7,001,638,477 | 0 | 7,001,638,477 | 0 | SCHEDULE 13G, 2026-08-07 |
The latest filing identifies Akari Therapeutics Plc by CUSIP 00972G405 and gives its principal executive office as 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL 33602 (SCHEDULE 13G, 2026-08-12).
What the percentages are based on
8.0% Percent of class calculated on a partially-diluted basis using 91,567,009,533 Ordinary Shares, par value $0.000000005, outstanding as of March 31, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission on May 19, 2026.MMCAP International Inc. SPC, SCHEDULE 13G, 2026-06-08
Purpose of Transaction (Item 4)
Samir R. Patel
On December 17, 2025, Dr. Patel purchased the securities described in the transactions as described in Item 3 above.Item 4 of the SCHEDULE 13D/A filed 2026-03-04
Ray Prudo, M.D.
On December 17, 2025, Dr. Prudo purchased the securities described in the transactions as described in Item 3 above.Item 4 of the SCHEDULE 13D/A filed 2026-03-04
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-04 | Hoyoung Huh, M.D., Ph.D. | 18.4% | SCHEDULE 13G/A |
| 2026-03-04 | Samir R. Patel | 10.4% | SCHEDULE 13D/A |
| 2026-03-04 | Ray Prudo, M.D. | 8.9% | SCHEDULE 13D/A |
| 2026-06-08 | MMCAP International Inc. SPC | 8% | SCHEDULE 13G |
| 2026-08-07 | White Lion Capital LLC | 5% | SCHEDULE 13G |
| 2026-08-12 | Bank of Montreal | 5.71% | SCHEDULE 13G |
Questions about who owns Akari Therapeutics Plc
Who owns Akari Therapeutics Plc?
On this page, 6 holders' latest ownership filings report 5% or more of Akari Therapeutics Plc: Hoyoung Huh, M.D., Ph.D. (18.4%, Schedule 13G/A, filed 2026-03-04), Samir R. Patel (10.4%, Schedule 13D/A, filed 2026-03-04), Ray Prudo, M.D. (8.9%, Schedule 13D/A, filed 2026-03-04), MMCAP International Inc. SPC (8%, Schedule 13G, filed 2026-06-08) and Bank of Montreal (5.71%, Schedule 13G, filed 2026-08-12); 1 more is listed above.
Who are the largest shareholders of Akari Therapeutics Plc?
By the share each holder's latest filing reports, the largest holders of Akari Therapeutics Plc on this page are Hoyoung Huh, M.D., Ph.D. (18.4%), Samir R. Patel (10.4%) and Ray Prudo, M.D. (8.9%).
When did Hoyoung Huh, M.D., Ph.D. buy into Akari Therapeutics Plc?
The filings give report dates, not purchase dates. The earliest filing from Hoyoung Huh, M.D., Ph.D. on this page is the Schedule 13G/A, filed 2026-03-04, reporting 18.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Akari Therapeutics Plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 3, 2026 | Form D, private offering | $1.83M sold | Form D page | Source |
| October 24, 2025 | Form D, private offering | $6.25M sold | Form D page | Source |
Akari Therapeutics Plc: every filing and event
Tools for this story
Each opens in a new tab, filled in for Akari Therapeutics Plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.